Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Table 4

One-factor analysis carried out using the Cox proportional hazard model over a 24-month follow-up period.

—		HR	(-95%; 95% confidence interval)
CST pre	0.01	0.84	(0.73; 0.96)
CST post	0.026	0.76	(0.59; 0,97)
CST δ%	<0.001	1.0041	(1.0017; 1.0065)
Age (years)	0.94	1	(0.94; 1.07)
Men	0.98	1	(1; 1)
EF	0.71	0.99	(0.91; 1.07)
TAPSE	0.12	0.89	(0.76;1.03)
Ischaemic aetiology	0.38	0.50	(0.11; 2.33)
BMI	0.29	0.93	(0.82; 1.06)
NYHA III	0.58	0.65	(0.14; 3.01)
Insulin	0.91	1.13	(0.14; 8.80)
AF	0.09	2.88	(0.84; 9.85)
ICD	0.45	1.61	(0.47; 5.51)
Hgb	0.86	0.96	(0.58; 1.57)
RDW	0.13	1.27	(0.93; 1.93)
WBC	0.61	1.08	(0.80; 1.47)
Neutrocytes	0.79	1.01	(0.94; 1.98)
TnTpre	0.31	1.28	(0.23; 0.72)
NT-proBNPpre	0.85	1.00	1
NT-proBNP post	0.83	1.00	1
NT-proBNP δ%	0.18	0.96	(0.90; 1.02)
V02max/V02peak	0.85	1.01	(0.90; 1.14)
OUES	0.06	0.41	(0.16; 1.02)
Ve/VCo2	0.44	1.03	(0.96; 1.11)
Hs-CRP	0.61	0.92	(0.65; 1.28)